These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-000349-20 Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical Carcinoma 2014-04-02 due-trials
Ongoing 2008-004874-42 Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen Mark... not-yet-due
Reported results 2016-003102-14 A PHASE II ONE-ARM OPEN-LABEL NEOADJUVANT STUDY OF PEMBROLIZUMAB IN COMBINATION WITH NAB-PACLITAXEL FOLLOWED BY PEMBROLIZUMAB IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH TRIPL... 2020-08-27 due-trials
Ongoing 2020-001938-35 AIRE: – ASSESSING IMMUNORESPONSE POST ERIBULIN: ERIBULIN AND IMMUNOGENICITY IN ADVANCED BREAST CANCER – A PROSPECTIVELY RANDOMIZED PHASE IV STUDY AIRE: Ermittlung der Immunantwort nach Eribulin: ... not-yet-due
Other 2020-001940-25 A PHASE II OPEN-LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2 NEGATIVE BREAST CANCER AND A ... not-yet-due
Completed, report not yet due 2020-001943-21 NeoOn – Neoadjuvant treatment of Ontruzant® (SB3) in patients with HER2-positive early breast cancer: An open-label, multicenter, phase IV study NeoOn – Neoadjuvante Behandlung von Patientinnen mit... 2024-01-23 not-yet-due